

Clinical Study

High-Flow Nasal Interface Improves Oxygenation in Patients Undergoing Bronchoscopy

Umberto Lucangelo,¹ Fabio Giuseppe Vassallo,² Emanuele Marras,¹ Massimo Ferluga,¹ Elena Beziza,¹ Lucia Comuzzi,¹ Giorgio Berlot,¹ and Walter Araujo Zin³

¹ Department of Perioperative Medicine, Intensive Care and Emergency, Cattinara Hospital, Trieste University School of Medicine, Strada di Fiume 447, 34149 Trieste, Italy

² Department of Pneumology, Cattinara Hospital, 34149 Trieste, Italy

³ Carlos Chagas Filho Institute of Biophysics, Federal University of Rio de Janeiro, 21949-900 RJ Rio de Janeiro, Brazil

Correspondence should be addressed to Umberto Lucangelo, u.lucangelo@fmc.units.it

Received 26 January 2012; Revised 22 March 2012; Accepted 23 March 2012

Academic Editor: Daniel De Backer

Copyright © 2012 Umberto Lucangelo et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

During bronchoscopy hypoxemia is commonly found and oxygen supply can be delivered by interfaces fed with high gas flows. Recently, the high-flow nasal cannula (HFNC) has been introduced for oxygen therapy in adults, but they have not been used so far during bronchoscopy in adults. Forty-five patients were randomly assigned to 3 groups receiving oxygen: 40 L/min through a Venturi mask (V40, $N = 15$), nasal cannula (N40, $N = 15$), and 60 L/min through a nasal cannula (N60, $N = 15$) during bronchoscopy. Gas exchange and circulatory variables were sampled before ($FiO_2 = 0.21$), at the end of bronchoscopy ($FiO_2 = 0.5$), and thereafter (V40, $FiO_2 = 0.35$). In 8 healthy volunteers oxygen was randomly delivered according to V40, N40, and N60 settings, and airway pressure was measured. At the end of bronchoscopy, N60 presented higher PaO_2 , PaO_2/FiO_2 , and SpO_2 than V40 and N40 that did not differ between them. In the volunteers (N60) median airway pressure amounted to 3.6 cmH₂O. Under a flow rate of 40 L/min both the Venturi mask and HFNC behaved similarly, but nasal cannula associated with a 60 L/min flow produced the better results, thus indicating its use in mild respiratory dysfunctions.

1. Introduction

During bronchoscopy hypoxemia is commonly found [1–3]. PaO_2 usually drops approximately 20 mmHg during the procedure [1, 4], and the worst decrease occurs during bronchoalveolar lavage (BAL) [5]. Age, gender, and baseline peripheral oxygen saturation (SpO_2) are not reliable predictive variables of hypoxemia [6] that may persist several hours after the procedure [1, 7] and increase the incidence of cardiac arrhythmia [8].

To avoid bronchoscopy-induced hypoxemia, oxygen supply can be delivered by interfaces fed with low (6 L/min) or high gas flows. Low-flow systems supply oxygen according to the patients' respiratory pattern, which limits their use [9]. Hence, clinically high-flow interfaces are generally used, and among them the Venturi mask has been the most

commonly employed device. Recently, the high-flow nasal cannula (HFNC) has been introduced for oxygen therapy in adults [10–13], as a natural extension of their use in neonates and children [14–16]. The effectiveness of both devices has been compared so far in adult human beings with acute respiratory failure in a sequential interventional study [11] and in a randomized work in patients with mild to moderate hypoxemic respiratory failure [12]. Both groups report a better performance of the HFNC device using maximum flows of 30 and 35 L/min, respectively. Additionally, to our knowledge these cannulas and heated/humidified circuits have not been used so far during bronchoscopy in adult human beings. Finally, a CPAP-like effect was reported in patients [17] and healthy volunteers [18] using a high-flow nasal cannula. Furthermore, it seems to display a flow-dependent behaviour [18].

Thus, we aimed at determining the effects of high-flow devices on gas exchange and cardiovascular variables in patients undergoing bronchoscopy and BAL. In all instances oxygen was supplemented by a Venturi mask or by a high-flow nasal cannula. Furthermore, two gas flow rates were applied to the latter device in order to better understand its biophysical/clinical behaviour. We compared not only the different devices/flows but also the same device along the overall bronchoscopy procedure. To verify whether a CPAP could be developed by high-flow rates, healthy awake volunteers were studied.

2. Materials and Methods

2.1. Study Design. Forty-five patients (21 females and 24 males) ranging from 37 to 83 years of age and with a body mass index (BMI) ranging from 21 to 30 (Table 1) were enrolled in the study that had been approved by our institutional review board. Informed signed consent was obtained from all patients. The clinical indications for bronchoscopy were idiopathic lung consolidation ($n = 19$); lung consolidation in the course of antibiotic therapy ($n = 10$); lung consolidation in immuno compromised patients ($n = 5$); eosinophilic pneumonia ($n = 3$); collagenopathy ($n = 2$); hemoptysis ($n = 2$); Churg-Strauss syndrome, asbestosis, lymphangioliomyomatosis, and alveolar microlithiasis ($n = 1$ in each case).

2.2. Methods. All patients were selected by the Pneumology Department, Cattinara University Hospital, to undergo fiberoptic bronchoscopy and BAL fluid collection as a diagnostic tool for pulmonary disease. They were included in the study if peripheral arterial pulse oximetry (SpO_2) was $\geq 90\%$, age ≥ 18 years, did not present either respiratory or cardiac failure, and were able to breathe spontaneously throughout fiberoptic bronchoscopy. Those subjects with body mass index (BMI) ≥ 30 , tracheostomy, requiring home oxygen therapy and/or mechanical or noninvasive ventilation, nasal and/or nasopharyngeal disease, not able to clearly express themselves, and pregnancy were excluded from the study.

The patients were randomly assigned to three groups ($N = 15$ in each one) by a physician unaware of the study: groups V40 and N40 received oxygen (40 L/min, $\text{FiO}_2 = 0.5$) through a Venturi mask (OS/62 K, FIAB, Vicchio, Italy) and HFNC (RT050, Fisher & Paykel, Auckland, New Zealand) during bronchoscopy, respectively (Figures 1(a) and 1(b), resp.). N60 patients also received oxygen through the aforementioned HFNC during bronchoscopy, but a higher flow rate was delivered (60 L/min, $\text{FiO}_2 = 0.5$), as shown in Figure 1(b). Oxygen/air mixture in V40 group was controlled by an air entrainer with the Venturi effect (RT008, Fisher & Paykel, Auckland, New Zealand), whereas in N40 and N60 a continuous high-flow generator with Venturi effect (9293/D, Harol, San Donato, Italy) was used. In all instances the patients were in the supine position, and the administered gas mixture was humidified and warmed by a servo-controlled heated respiratory humidifier (MR730, Fisher & Paykel, Auckland, New Zealand), as depicted in

Figure 1. FiO_2 was measured on the inspiratory line by an oxymeter (5120 Oxygen Monitor, Datex-Ohmeda, Inc, Madison, WI, USA) (Figure 1). Baseline PaO_2 , PaCO_2 , pH (Rapidlab 865, Bayer, Leverkusen, Germany), SpO_2 , heart rate (HR), and non-invasive mean arterial pressure (MAP) (Dinamap, General Electrics, WI, USA) were measured during spontaneous breathing in room air (t_0 , Table 1). PAO_2 was calculated by the alveolar gas equation, assuming the respiratory quotient equal to 0.8 and barometric pressure as 760 mmHg. Arterial/alveolar PO_2 ratio (a/APO_2) and ratio between PaO_2 and inspiratory fraction of oxygen ($\text{PaO}_2/\text{FiO}_2$) were then arithmetically calculated. A venous catheter was indwelled to secure a line for administration of drugs and saline solution. After 5 min of oxygen ($\text{FiO}_2 = 0.5$) administration, local anaesthesia (nebulised lidocaine 2%, 8–10 mL) was performed through the mouth and nostrils. A 10 min resting period was allowed to guarantee fully developed local anaesthesia. Conscious intravenous sedation was achieved by means of midazolam delivered as demanded by each patient, reaching a maximum dose of 0.1 mg/kg BW. Fiberoptic bronchoscopy (18-F, Olympus Corp, Tokyo, Japan) was immediately initiated through a dedicated mouthpiece (Pentax Europe GmbH, Hamburg, Germany). Bronchoalveolar lavage was done with 150 mL of warmed saline solution (NaCl 0.9%) and fluid was aspirated always by the same pneumologist, who had not later access to the raw data. At this point gas exchange and circulatory variables were sampled (t_1). At the end of the procedure that lasted from 8 to 34 min, all patients were switched to V40 setting with a $\text{FiO}_2 = 0.35$ for a resting period of 10 min. Then (t_2), the last data sampling took place.

Before discharging the patient from the bronchoscopy room, he/she was asked to describe the level of comfort during the procedure according to a scale: 1 = excellent, 2 = good, 3 = mild, and 4 = poor.

Additionally, eight healthy volunteers ranging from 25 to 37 years of age and presenting 20 to 24 BMI (4 females and 4 males) rested in supine position and underwent local anaesthesia as aforementioned. A 35 cm long 14-F catheter (Willy Rüschi GmbH, Kernlen, Germany) with two side-holes and another distal one were introduced through the nostril, its distal end reaching the hypopharynx. Its correct positioning in the pharynx was detected by gas sampling and CO_2 monitoring ($\text{CO}_2\text{SMO Plus 8100}$, Novamatrix Medical System, Inc., Wallingford, CT, USA) as follows: when a normal capnographic curve resulted, the catheter was considered correctly placed; otherwise it was moved up and down until adequately positioned. The volunteers were attached to the dedicated mouthpiece (Pentax Europe GmbH, Hamburg, Germany) partially obstructed by an occluded tracheal tube (size 5, OD 6.7 mm, Rüschi GmbH, Kernlen, Germany) that simulated the fiberoptic bronchoscope. The tracheal tube distal end was always within the mouthpiece. Oxygen ($\text{FiO}_2 = 0.28$) was randomly delivered according to V40, N40, and N60 settings, and airway pressure was measured through the nasally introduced catheter by the $\text{CO}_2\text{SMO Plus 8100}$ Respiratory Profile Monitor (Novamatrix Medical System, Inc., Wallingford, CT, USA). A 5 min resting period was allowed between

TABLE 1: Anthropometric, respiratory, and cardiovascular data under facial and different nasal interfaces.

Variables	V40	N40	N60
Baseline (t_0 , $FiO_2 = 0.21$)			
Gender (M/F)	9/6	8/7	7/8
Age (years)	68.0 (62.0–78.0)	70.0 (61.0–76.0)	64.0 (63.0–70.0)
BMI (kg/m ²)	26.5 (22.5–29.1)	25.0 (21.4–28.0)	25.7 (21.2–28.9)
pH	7.45 (7.44–7.48)	7.47 (7.43–7.49)	7.46 (7.42–7.47)
PaCO ₂ (mmHg)	37.5 (35.0–42.1)	39.1 (37.3–41.5)	39.6 (33.4–42.5)
PaO ₂ /FiO ₂	322.4 (295.6–374.3)	342.8 (295.7–371.9)	350.9 (304.3–363.8)
a/A PO ₂	0.674 (0.587–0.764)	0.723 (0.652–0.745)	0.718 (0.659–0.765)
PaO ₂ (mmHg)	67.7 (62.1–78.6)	72.0 (62.1–78.1)	73.7 (63.9–76.4)
SpO ₂ (%)	94 (93–96)	95 (91–96)	95 (93–97)
HR (bpm)	75.0 (62.0–97.0)	78.0 (72.0–85.0)	74.0 (68.0–84.0)
MAP (mmHg)	94.0 (90.0–107.0)	102.0 (92.0–112.0)	109.0 (100.0–117.0)
End of bronchoscopy (t_1 , $FiO_2 = 0.50$)			
pH	7.41 (7.38–7.44)*	7.41 (7.38–7.44)*	7.40 (7.36–7.40)*
PaCO ₂ (mmHg)	42.7 (41.0–44.4)*	43.2 (37.9–47.6)*	43.6 (42.4–48.0)*,+
PaO ₂ /FiO ₂	165.0 (127.4–199.2)*	140.6 (125.6–153.6)*	244.8 (181.6–366.8)*,++
a/A PO ₂	0.265 (0.207–0.326)*	0.224 (0.204–0.249)*	0.401 (0.295–0.604)*,+,++
PaO ₂ (mmHg)	82.5 (63.7–99.6)	70.3 (62.8–76.8)	122.4 (90.8–183.4)*,++
SpO ₂ (%)	94 (92–96)	92 (90–95)	98 (97–99)*,+,++
HR (bpm)	90 (76–110)*	84 (80–101)	84 (70–100)*
MAP (mmHg)	108.0 (92.0–126.0)	99.0 (94.0–105.0)	103.0 (93.0–117.0)
Duration (min)	14.0 (10.0–16.0)	15.0 (12.0–16.0)	15.0 (9.0–20.0)
10 minutes after bronchoscopy (t_2 , $FiO_2 = 0.35$)			
pH	7.42 (7.40–7.45)*	7.41 (7.39–7.44)*,***	7.40 (7.40–7.44)*,***
PaCO ₂ (mmHg)	42.2 (39.7–43.2)*	43.4 (41.0–45.7)*	40.7 (38.0–45.5)
PaO ₂ /FiO ₂	248.6 (206.6–274.3)*,***	224.3 (206.6–249.1)*,***	278.8 (222.9–304.0)*
a/A PO ₂	0.441 (0.342–0.515)*,***	0.421 (0.352–0.446)*,***	0.480 (0.389–0.536)*
PaO ₂ (mmHg)	87.0 (72.3–101.8)	78.5 (72.3–87.2)	97.6 (78.0–106.4)*,***
SpO ₂ (%)	95 (92–98)	93 (91–95)	95 (95–98)*,+,+
HR (bpm)	82.0 (75.0–90.0)**	80.0 (79.0–91.0)*	76.0 (64.0–89.0)**
MAP (mmHg)	91.0 (83.0–103.0)	94.0 (85.0–98.0)**	96.0 (87.0–108.0)

Values are median (1st–3rd quartiles). V40, N40: patients that received oxygen (40 L/min, $FiO_2 = 0.5$) through a Venturi mask and nasal prong; respectively, N60: patients that received oxygen (60 L/min, $FiO_2 = 0.5$) through a nasal high-flow interface; baseline: $FiO_2 = 0.21$; end of bronchoscopy: airflow according to V40, N40, and N60, $FiO_2 = 0.5$; 10 min after bronchoscopy: 15 L/min, $FiO_2 = 0.35$; PaCO₂ and PaO₂: arterial partial pressures of CO₂ and O₂; respectively, BMI: body mass index; PaO₂/FiO₂: ratio between PaO₂ and inspiratory fraction of O₂; a/A PO₂: ratio between arterial and alveolar PO₂; SpO₂: peripheral oxygen saturation; HR: heart rate; MAP: mean arterial pressure, duration: length of bronchoscopy. *Significantly different from t_0 ; **significantly different from t_1 ; +significantly different from V40; ++significantly different from N40; significance level = 5%.

two different oxygen delivery settings. In all instances the experiment did not last more than 30 min.

2.3. Analysis. Statistical analysis was performed using Statistica 6.1 software (StatSoft, Vigonza, Italy). Normality was assessed by the Kolmogorov-Smirnov-Lilliefors test. Since in all instances normal distribution was not satisfied, descriptive statistics were provided using median and 1st–3rd quartiles. Mann-Whitney and the Wilcoxon tests were used to pairwise compare data among different oxygen delivery systems/flows and among diverse points along the experimental timeline, respectively. Multiple comparisons were controlled for the false discovery rate [19, 20]. In all instances, the initial significance level was set at 5%, and the adjusted P values are provided when significant.

A 3-sample test for equality of proportions was used to evaluate the male/female distribution. The level of comfort was assessed by permutation tests implemented in R coin package [21]. Significance level was 5%.

3. Results

Patients' anthropometric and experimental data are listed in Table 1. The results will be presented firstly as function of time (t_0 , t_1 , t_2) and, then, among groups (N40, N60, V40).

At time t_0 no difference among the 3 groups could be disclosed (Table 1). At the end of bronchoscopy (t_1), in N60 patients a/A PO₂, PaO₂/FiO₂, and SpO₂ were larger than those in V40 and N40. In N60 PaO₂ and PaCO₂ were higher than those in N40 and V40, respectively. V40 and N40 did




FIGURE 1: Diagram of the experimental setups. (a) Setup used for a flow rate of 40 L/min. (1) Venturi mask. (2) Pneumotachograph. (3) Oxymeter. (4) Heater/humidifier. (5) Air entrainer with the Venturi effect. (6) Wall mounted oxygen supply. (b) Setup used for delivering an airflow of 60 L/min. (1) High-flow nasal cannula. (2) Pneumotachograph. (3) Oxymeter. (4) Heater/humidifier. (5) Continuous high-flow generator with the Venturi effect.

not differ between in all instances. No differences in pH, HR, and MAP values were found among the groups. Ten minutes after the end of bronchoscopy (t_2), SpO₂ between N60 and V40 was the only detected difference.

In V40 group a/A PO₂ and PaO₂/FiO₂ presented different values in all occasions. PaCO₂ was smaller, and pH was higher in t_0 than that in t_1 and t_2 . HR was higher in t_1 than in t_0 and t_2 . In N40 group a/A PO₂, PaO₂/FiO₂, and pH presented different values at all times. PaCO₂ was smaller in t_0 than in t_1 and t_2 . HR and MAP were higher in t_2 than in t_0 and t_1 , respectively. In N60 group PaO₂ and pH presented different values in all instances, a/A PO₂ was higher in t_0 than in t_1 and t_2 , and PaO₂/FiO₂ was higher in t_0 than in t_2 . SpO₂ and HR were higher in t_1 than in t_0 and t_2 , and PaCO₂ was smaller in t_0 than in t_1 (Table 1).

Bronchoscopy duration was similar in all groups (15, 14, and 15 min in V40, N40, and N60, resp., $P = 0.69$) as well as the amount of midazolam used (4 mg in each group, $P = 0.95$). Bronchoalveolar lavage fluid aspirated was smaller in V40 (43 mL) than in N40 (75 mL) and N60 (73 mL) that did not differ in between, ($P = 0.0005$). Gender, age and BMI did not differ among the groups (Table 1).

There was no difference among the level of comfort among V40 (level 4 = 7, level 3 = 6, and level 2 = 2), N40 (level 4 = 9, level 3 = 5, and level 2 = 1), and N60 (level 4 = 8, level 3 = 7), $P = 0.569$.

Finally, in the normal volunteers end-expiratory airway pressure amounted to 3.6 (2.4–4.0) cmH₂O (median (1st–3rd quartiles)) using a high-flow nasal cannula and undergoing a flow of 60 L/min. In the other two experimental settings, no measurable end-expiratory pressure was detected.

4. Discussion

During bronchoscopy gas exchange is usually impaired owing to sedation and mismatching of the ventilation-perfusion relationship (bronchoalveolar lavage, increased airway resistance due to the presence of the fiberoptic bronchoscope, and gas aspiration through the fiberoptic

bronchoscope that may result in atelectasis) [22]. Hypoxemia can be treated with low- and high-flow oxygen delivery [1]. For such purpose the Venturi mask is commonly used. Recently, the high-flow nasal cannula has been introduced for oxygen therapy in adults [10–13, 23]. To our knowledge these cannulas have not been used so far during bronchoscopy in adults. Thus, we aimed at determining the effects of high-flow devices on gas exchange and cardiovascular variables in patients undergoing bronchoscopy and BAL. To verify whether a CPAP could be developed by high-flow rates, healthy awake volunteers were studied.

High-flow rates reduce the nasopharyngeal dead space, thus improving ventilation and oxygenation [11, 12, 24]. Mouth breathing may increase this phenomenon as a result of the reservoir effect produced by the mouth and nasopharynx gas volume [18]. In our patients oxygenation was further improved by a FiO₂ equal to 50% during bronchoscopy. Furthermore, humidified and warmed high flows improve lung conductance and compliance, inhibiting bronchoconstriction and reducing the metabolic cost of O₂ [24].

Our 3 groups of patients presented similar demographic characteristics. Despite the statistically significant results obtained for some variables in our study, only the differences that presented clinical relevance will be discussed. In all instances, no difference in respiratory and cardiovascular measurements could be found between V40 and N40. Thus, at this flow rate both devices were equally effective. However, under N60 a/A PO₂, SpO₂, and PaO₂/FiO₂ were higher than those in V40 and N40, thus indicating a better oxygenation under these experimental conditions at the end of bronchoscopy. Indeed, in N60 a/A PO₂ and PaO₂/FiO₂ did not vary significantly between the end of bronchoscopy and 10 min after bronchoscopy, whereas the values at the three experimental sampling occasions differed among them in V40 and N40. We calculated the PaO₂/FiO₂ and the a/A ratio because they are relatively unaffected by FiO₂ and in particular the a/A ratio is less dependent on the patient's age [25, 26]. In this way, the absolute PaO₂ value assumes a secondary clinical relevance.

Carbon dioxide kinetics returned to baseline values in N60 while in V40 and N40 at 10 minutes after bronchoscopy. PaCO₂ did not return to control levels. However, several studies reported different PaCO₂ behaviours during HFNC, and thus the carbon dioxide wash-out mechanism is still not widely accepted [27] as the main physiological effect under this condition.

Possibly the development of CPAP owing to the even higher flow rate achieved with the HFNC, a smaller possibility to dilute the delivered mixture by room air, and a more constant FiO₂ would explain these findings [27, 28]. The Venturi mask could not be tested with 60 L/min because of a technical limitation of the air entrainer itself, as stated by the manufacturer (RT008, Fisher & Paykel, Auckland, New Zealand, REF 185041357 Rev E 2009-07). Our results demonstrated that the association of HFNC and 60 L/min flow provided the better oxygenation not only during bronchoscopy but also during recovery. HFNC with smaller flow than ours also proved to be more effective than the face mask in hypoxemic respiratory failure [11, 12].

In our study we chose an oxygen delivery of 50% in order to minimize hypoxemia during bronchoscopy. After the procedure, during 10 minutes an oxygen delivery of 35% was used to evaluate the patients' recovery.

We ran a second set of experiments on healthy volunteers to verify whether a CPAP could indeed be developed by high-flow rates. This measurement was not done in the patients to avoid an undesirable extra burden during the procedure. The volunteers underwent the same three settings applied to the patients. The volunteers' median airway pressure under V40 and N40 settings was nil, but a value of 3.6 cmH₂O was measured at end expiration under N60 conditions in volunteers with a partially obstructed mouth. Our results are in line with those previously reported. Indeed, a CPAP-like effect has been recently reported in postoperative cardiac surgery patients (2.7 cmH₂O, 35 L/min) [17] and in normal volunteers (2.7 cmH₂O open mouth, and 7.4 cmH₂O closed mouth, 60 L/min) [18], and it has been demonstrated that positive nasopharyngeal pressure increases with increasing flow [18]. This CPAP could possibly contribute to the better oxygenation in our patients.

Since the level of comfort was identical in the three groups of patients, one can possibly assume that the three experimental settings were similarly supported by them. Furthermore, our patients tolerated very well the HFNC. In this line, it has been demonstrated that patients chose to continue with HFNC after having tried it [11].

In conclusion, under a flow rate of 40 L/min both the Venturi mask and the high flow nasal cannula behaved similarly, but the outcome produced by the latter associated with a flow of 60 L/min was clinically more important. Perhaps the latter association could protect to a larger extent patients with mild respiratory dysfunctions.

Acknowledgments

Support was provided solely by institutional and/or departmental sources: the Cattinara Hospital, University of Trieste,

Trieste, Italy. W. A. Zin (Visiting Professor) was partially supported by the Rio de Janeiro Research Supporting Foundation (FAPERJ) and the Brazilian Council for Scientific and Technological Development (CNPq), Brazil. The authors are also indebted to Mr. Giuliano Marras for providing the artwork used in the paper.

References

- [1] R. Albertini, J. H. Harrel, and K. M. Moser, "Letter: hypoxemia during fiberoptic bronchoscopy," *Chest*, vol. 65, no. 1, pp. 117–118, 1974.
- [2] L. Papazian, H. G. Colt, F. Scemama, C. Martin, and F. Gouin, "Effects of consecutive protected specimen brushing and bronchoalveolar lavage on gas exchange and hemodynamics in ventilated patients," *Chest*, vol. 104, no. 5, pp. 1548–1552, 1993.
- [3] G. P. Randazzo and A. F. Wilson, "Cardiopulmonary changes during flexible fiberoptic bronchoscopy," *Respiration*, vol. 33, no. 2, pp. 143–149, 1976.
- [4] Y. Matsushima, R. L. Jones, and E. G. King, "Alterations in pulmonary mechanics and gas exchange during routine fiberoptic bronchoscopy," *Chest*, vol. 86, no. 2, pp. 184–188, 1984.
- [5] M. Pirozynski, P. Sliwinski, L. Radwan, and J. Zielinski, "Bronchoalveolar lavage: comparison of three commonly used procedures," *Respiration*, vol. 58, no. 2, pp. 72–76, 1991.
- [6] W. F. Fang, Y. C. Chen, Y. H. Chung et al., "Predictors of oxygen desaturation in patients undergoing diagnostic bronchoscopy," *Chang Gung Medical Journal*, vol. 29, no. 3, pp. 306–312, 2006.
- [7] P. Montravers, R. Gauzit, M. C. Dombret, F. Blanchet, and J. M. Desmots, "Cardiopulmonary effects of bronchoalveolar lavage in critically ill patients," *Chest*, vol. 104, no. 5, pp. 1541–1547, 1993.
- [8] D. L. Shrader and S. Lakshminarayan, "The effect of fiberoptic bronchoscopy on cardiac rhythm," *Chest*, vol. 73, no. 6, pp. 821–824, 1978.
- [9] B. A. Shapiro, W. T. Peruzzi, and R. Kozlowski-Templin, *Clinical Application of Blood Gases*, Mosby, St. Louis, Mo, USA, 5th edition, 1994.
- [10] J. B. Waugh and W. M. Granger, "An evaluation of 2 new devices for nasal high-flow gas therapy," *Respiratory care*, vol. 49, no. 8, pp. 902–906, 2004.
- [11] O. Roca, J. Riera, F. Torres, and J. R. Masclans, "High-flow oxygen therapy in acute respiratory failure," *Respiratory Care*, vol. 55, no. 4, pp. 408–413, 2010.
- [12] R. L. Parke, S. P. McGuinness, and M. L. Eccleston, "A preliminary randomized controlled trial to assess effectiveness of nasal high-flow oxygen in intensive care patients," *Respiratory Care*, vol. 56, no. 3, pp. 265–270, 2011.
- [13] J. M. Carratalá Perales, P. Llorens, B. Brouzet et al., "High-flow therapy via nasal cannula in acute heart failure," *Revista Espanola de Cardiologia*, vol. 64, pp. 723–725, 2011.
- [14] R. G. Locke, M. R. Wolfson, T. H. Shaffer, S. D. Rubenstein, and J. S. Greenspan, "Inadvertent administration of positive end-distending pressure during nasal cannula flow," *Pediatrics*, vol. 91, no. 1, pp. 135–138, 1993.
- [15] J. G. Saslow, Z. H. Aghai, T. A. Nakhla et al., "Work of breathing using high-flow nasal cannula in preterm infants," *Journal of Perinatology*, vol. 26, no. 8, pp. 476–480, 2006.
- [16] C. Sreenan, R. P. Lemke, A. Hudson-Mason, and H. Osioviich, "High-flow nasal cannulae in the management of apnea of

- prematurity: a comparison with conventional nasal continuous positive airway pressure,” *Pediatrics*, vol. 107, no. 5, pp. 1081–1083, 2001.
- [17] R. Parke, S. McGuinness, and M. Eccleston, “Nasal high-flow therapy delivers low level positive airway pressure,” *British Journal of Anaesthesia*, vol. 103, no. 6, pp. 886–890, 2009.
- [18] N. Groves and A. Tobin, “High flow nasal oxygen generates positive airway pressure in adult volunteers,” *Australian Critical Care*, vol. 20, no. 4, pp. 126–131, 2007.
- [19] D. Curran-Everett and D. J. Benos, “Guidelines for reporting statistics in journals published by the American Physiological Society,” *American Journal of Physiology*, vol. 28, pp. 85–87, 2004.
- [20] Y. Benjamini and Y. Hochberg, “Controlling the false discovery rate: a practical and powerful approach to multiple testing,” *Journal of the Royal Statistical Society: Series B*, vol. 57, no. 1, pp. 289–300, 1995.
- [21] T. Hothorn, M. A. Van De Wiel, K. Hornik, and A. Zeileis, “Implementing a class of permutation tests: the coin package,” *Journal of Statistical Software*, vol. 28, no. 8, pp. 1–23, 2008.
- [22] B. B. Brach, G. G. Escano, J. H. Harrell, and K. M. Moser, “Ventilation perfusion alterations induced by fiberoptic bronchoscopy,” *Chest*, vol. 69, no. 3, pp. 335–337, 1976.
- [23] A. M. Price, C. Plowright, A. Makowski, and B. Misztal, “Using a high-flow respiratory system (Vapotherm) within a high dependency setting,” *Nursing in Critical Care*, vol. 13, no. 6, pp. 298–304, 2008.
- [24] K. Dysart, T. L. Miller, M. R. Wolfson, and T. H. Shaffer, “Research in high flow therapy: mechanisms of action,” *Respiratory Medicine*, vol. 103, no. 10, pp. 1400–1405, 2009.
- [25] R. Gilbert and J. F. Keighley, “The arterial/alveolar oxygen tension ratio. An index of gas exchange applicable to varying inspired oxygen concentrations,” *American Review of Respiratory Disease*, vol. 109, no. 1, pp. 142–145, 1974.
- [26] G. C. Carroll, “Misapplication of alveolar gas equation,” *New England Journal of Medicine*, vol. 312, no. 9, p. 586, 1985.
- [27] J. Kernick and J. Magarey, “What is the evidence for the use of high flow nasal cannula oxygen in adult patients admitted to critical care units? A systematic review,” *Australian Critical Care*, vol. 23, no. 2, pp. 53–70, 2010.
- [28] R. B. Wettstein, D. C. Sheldedy, and J. I. Peters, “Delivered oxygen concentrations using low-flow and high-flow nasal cannulas,” *Respiratory Care*, vol. 50, pp. 604–609, 2005.